Jazz Pharmaceuticals
JAZZ
468 hedge funds and large institutions have $7.76B invested in Jazz Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 157 increasing their positions, 148 reducing their positions, and 54 closing their positions.
81% more call options, than puts
Call options by funds: $65.9M | Put options by funds: $36.3M
9% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 54
6% more repeat investments, than reductions
Existing positions increased: 157 | Existing positions reduced: 148
0.84% more ownership
Funds ownership: 92.03% → 92.87% (+0.84%)
0% more funds holding
Funds holding: 468 → 468 (0)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
13% less capital invested
Capital invested by funds: $8.89B → $7.76B (-$1.13B)
Top Buyers
Top Sellers
JAZZ Hedge Fund Activity: Q3 2022 in Review
468 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2022, worth a combined $7.76B — down 13% from $8.89B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new JAZZ positions and 54 closed out — a net gain of 5 holders — while 157 added to existing stakes and 148 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $204M. The largest seller was Citadel Advisors, exiting entirely with an estimated $108M sold.
- 468 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $7.76B of Jazz Pharmaceuticals stock for Q3 2022, down 13% quarter-over-quarter.
- 59 funds opened new Jazz Pharmaceuticals positions in Q3 2022 and 54 closed out, a net change of +5 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2022 was Janus Henderson Group, an estimated $204M added.
- The largest Jazz Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2022.